1. Home
  2. ERC vs CLLS Comparison

ERC vs CLLS Comparison

Compare ERC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERC
  • CLLS
  • Stock Information
  • Founded
  • ERC 2003
  • CLLS 1999
  • Country
  • ERC United States
  • CLLS France
  • Employees
  • ERC N/A
  • CLLS N/A
  • Industry
  • ERC Finance/Investors Services
  • CLLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ERC Finance
  • CLLS Health Care
  • Exchange
  • ERC Nasdaq
  • CLLS Nasdaq
  • Market Cap
  • ERC 262.9M
  • CLLS 299.0M
  • IPO Year
  • ERC N/A
  • CLLS 2007
  • Fundamental
  • Price
  • ERC $9.72
  • CLLS $3.13
  • Analyst Decision
  • ERC
  • CLLS Buy
  • Analyst Count
  • ERC 0
  • CLLS 1
  • Target Price
  • ERC N/A
  • CLLS $4.00
  • AVG Volume (30 Days)
  • ERC 64.4K
  • CLLS 77.9K
  • Earning Date
  • ERC 01-01-0001
  • CLLS 11-03-2025
  • Dividend Yield
  • ERC 8.37%
  • CLLS N/A
  • EPS Growth
  • ERC N/A
  • CLLS N/A
  • EPS
  • ERC 0.72
  • CLLS N/A
  • Revenue
  • ERC N/A
  • CLLS $63,438,000.00
  • Revenue This Year
  • ERC N/A
  • CLLS N/A
  • Revenue Next Year
  • ERC N/A
  • CLLS $66.76
  • P/E Ratio
  • ERC $12.92
  • CLLS N/A
  • Revenue Growth
  • ERC N/A
  • CLLS 223.09
  • 52 Week Low
  • ERC $8.51
  • CLLS $1.10
  • 52 Week High
  • ERC $9.74
  • CLLS $3.35
  • Technical
  • Relative Strength Index (RSI)
  • ERC 70.05
  • CLLS 65.44
  • Support Level
  • ERC $9.47
  • CLLS $2.88
  • Resistance Level
  • ERC $9.72
  • CLLS $3.35
  • Average True Range (ATR)
  • ERC 0.06
  • CLLS 0.17
  • MACD
  • ERC 0.02
  • CLLS 0.02
  • Stochastic Oscillator
  • ERC 100.00
  • CLLS 74.12

About ERC Allspring Multi-Sector Income Fund

Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: